Merck says study shows COVID-19 drug causes quick reduction in virus – Reuters

FILE PHOTO: The Merck logo is seen at a gate to the Merck & & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid (Reuters) – U.S. drugmaker Merck & & Co Inc stated on Saturday the experimental antiviral drug molnupiravir it is establishing with Ridgeback Bio revealed a quicker decrease in infectious virus in its stage 2a research study amongst individuals with early COVID-19.” The secondary objective findings in this study, of a quicker decline in contagious virus among individuals with early COVID-19 treated with molnupiravir, are appealing,” said William Fischer, Associate Professor of Medicine at the University of North Carolina School of Medicine, in a statement from the companies.The antiviral is being presently tested in a Phase 2/3 trial that is set to be completed in May.Merck chose to focus on rehabs after its 2 COVID-19 vaccines failed to create wanted immune reactions, prompting it to desert the program in January.Reporting by Ann Maria Shibu in Bengaluru; Editing by Christian Schmollinger